Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02968433 · ClinicalTrials.gov registry record · Phase 1
The Stanford Parkinson's Disease Plasma Study
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02968433: Completed Phase 1 study, sponsored by Stanford University.
NCT02968433 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02968433, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that young plasma infusions can be performed safely in patients with Parkinson's Disease (PD). Secondary outcomes will include behavioral and laboratory data that will support the next study that will inquire whether young plasma infusions improve or slow the progression of cognitive, mood and/or motor impairment and rate markers of the disease.
Interventions
- DRUG Infusions of young plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-11 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02968433
The ClinicalTrials.gov registry entry for NCT02968433 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Infusions of young plasma is the first listed.
NCT02968433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02968433 about?
NCT02968433 is a clinical study titled "The Stanford Parkinson's Disease Plasma Study". The purpose of this study is to demonstrate that young plasma infusions can be performed safely in patients with Parkinson's Disease (PD). Secondary outcomes will include behavioral and laboratory data that will support the next study that will inquire whether young plasma infusions improve or slow ...
What is the current status of trial NCT02968433?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-11. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02968433?
The interventions under investigation include: Infusions of young plasma (DRUG).
Who is sponsoring clinical trial NCT02968433?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.